U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details


; ; .

Author Information and Affiliations

Last Update: August 22, 2023.

Continuing Education Activity

Hydroquinone cream is the standard depigmentation or skin lightening agent. Clinically it is used to treat areas of dyschromia, such as in melasma, chloasma, solar lentigines, freckles, and post-inflammatory hyperpigmentation. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, and monitoring of hydroquinone, so providers can direct patient therapy to optimal outcomes in conditions where it is indicated.


  • Outline the indications for using hydroquinone therapy.
  • Describe the mechanism of action of hydroquinone.
  • Summarize the potential adverse events associated with hydroquinone.
  • Review interprofessional team strategies for improving care coordination and communication to advance improved outcomes using hydroquinone when indicated.
Access free multiple choice questions on this topic.


Hydroquinone cream is the standard depigmentation or skin lightening agent. Clinically it is used to treat areas of dyschromia, such as in:

  • Melasma
  • Chloasma
  • Solar lentigines
  • Freckles
  • Post-inflammatory hyperpigmentation

Its most common use is in patients with post-inflammatory hyperpigmentation and melasma.

Post-inflammatory Hyperpigmentation

Postinflammatory hyperpigmentation results from cutaneous inflammation, causing increased melanin production. Common causes of postinflammatory hyperpigmentation are acne vulgaris, eczematous dermatoses, contact dermatitis, psoriasis, lichen planus, and burns.[1] The most common cause of hyperpigmentation results from photodamage from sunlight exposure.[2] Inflammation increases the release and oxidation of arachidonic acid to prostaglandins and leukotrienes, resulting in increased melanin production.[3] Hydroquinone is used to treat postinflammatory hyperpigmentation along with photoprotection. Improvement with hydroquinone occurs over several weeks to months.[4]


Melasma is an acquired hyperpigmentation condition and presents on sun-exposed areas of the face, commonly the forehead, cheeks, and chin.[5] It presents as symmetrically distributed pigmented macules and patches.[6] Factors that play a role in the pathogenesis of melasma are darker skin, UV radiation, hormones, genetics, and antiepileptic medications. Exposure to UV radiation is the main factor in pathogenesis as UV radiation increases alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone levels, which increases the proliferation of melanocytes.[7] Also, at the dermal layer, increased expression of stem cells of fibroblasts and tyrosine kinase receptor c-kit is present in melasma lesions. Also noted in lesions are upregulation of vascular endothelial growth factor (VEGF), Wnt, and reactive oxygen species seen after UV-induced dermal inflammation. Vascularization and melanocyte hyperreactivity results from this UV-induced inflammation leading to increased melanin production and hyperpigmentation. Patients who are pregnant or use oral contraceptives are also at risk because the expression of estrogen receptors seems to rise in melasma lesions as well.[8][6] Estrogen also induces the release of melanocyte-stimulating hormone (MSH), which stimulates tyrosinase leading to increased melanin production. For this reason, melasma occurs more frequently in females vs. males.[6] Treatment is similar to postinflammatory hyperpigmentation, with photoprotection and hydroquinone being the first line.

Photoprotection is a significant key in maximal benefit from hydroquinone use. Melanocytes become stimulated from UVB, UVA, and even visible light leading to pigmentation. Therefore, broad-spectrum sunscreens are a recommended strategy.[6]

Hydroquinone is not FDA approved due to its unknown safety profile. It is banned in the EU, Australia, and Japan.

Mechanism of Action

Hydroquinone acts as a skin depigmentation agent by inhibiting melanin synthesis. It inhibits the conversion of L-3,4- dihydroxyphenylalanine (L-DOPA) to melanin by inhibiting tyrosinase due to its structural similarity to an analog of melanin precursors.[6]

The Pathway of Melanin Synthesis [9]

  1. Hydroxylation of L-phenylalanine to L-tyrosine
  2. Tyrosinase hydroxylates L-tyrosine to 3,4 L-dihydroxyphenylalanine (L-DOPA)
  3. L-DOPA oxidized to dopaquinone
  4. Production of eumelanin and pheomelanin resulting in black to brown and yellow to red color of skin


Hydroquinone is only used topically as a depigmentation agent. A thin layer is applied with fingertips and rubbed into the face (or other affected areas) 1 to 2 times a day for 3 to 6 months. If there are no results after 2 to 3 months, hydroquinone should be discontinued. It is essential to evenly apply hydroquinone over the entire face to prevent uneven pigmentation and use concurrently with sunscreen to protect from damaging UV light, which increases pigmentation.  Physicians recommended stopping treatment after this time for a few months before restarting to decrease the risk of side effects. It can also be applied during weekends only or three times a week for more extended maintenance therapy with minimal complications.[6]

Hydroquinone is available in 2% over the counter or as 4% prescribed.[2] It comes in the following dose forms: cream, emulsion, gel, or solution.

Multiple studies have shown that maximum results occur when using hydroquinone as a combination therapy with a retinoid and corticosteroid. The most widely used triple combination cream is composed of hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%.[6] Use in combination with other agents requires a prescription by a dermatologist.

Results vary among each patient.

About 35% to 45% of hydroquinone is absorbed systemically after topical use.[10]

Adverse Effects

Adverse Effects Include [11] [6] [2]

  • Irritation
  • Allergic contact dermatitis
  • Erythema
  • Inflammation
  • Xeroderma
  • Stinging
  • Rarely ochronosis - ochronosis is a blue-black or gray-blue discoloration; it is rare and more commonly seen in patients that use a high concentration of hydroquinone for a long period on large areas of the body.

Studies also suggest that hydroquinone can falsely elevate capillary glucose when measured with a glucometer.[12]

There has been no confirmation regarding concerns that hydroquinone cream is carcinogenic either in clinical practice or human research.[6]


  • Allergic reaction or hypersensitivity hydroquinone 
  • Sun exposure
  • The use of this drug requires caution with other medications that cause photosensitivity.

Pregnancy Category C

About 35 to 45% of the topical hydroquinone dose is absorbed systemically. Current studies have not shown an increased risk of malformations or adverse effects in pregnant women, but it is recommended to minimize exposure due to the substantial absorption.[10] The safety of breastfeeding mothers and children remains unestablished, and as such, breastfeeding females should avoid this drug.


Monitor for any hypersensitivity or long-term irritation, in which case the medication should be discontinued. Also, in rare cases, ochronosis develops; the patient should stop using hydroquinone and consult a clinician.


No significant toxicity has been found with the topical use of the hydroquinone cream.

Some studies report malignancies in animals treated for an extended period with large oral doses.[2]

Hydroquinone in the Environment

In the environment, hydroquinone is a chemical and can be toxic in human and industrial activities by promoting the generation of reactive oxygen species, oxidative stress, and hence the potential for DNA damage. It is a major benzene metabolite and is known to be hepatotoxic and carcinogenic in these settings. Some studies suggest it can promote tumor cell growth and suppress the immune response. It is used in photography and is present in dyes, paints, varnishes oils, and motor fuels. In its oxidized form, it is more toxic and less degradable. It demonstrates high toxicity to aquatic organisms and rodents and may induce leukemia, renal tubular cell tumor, and liver cancer. It has also been found to influence immune cell responses and causes an increase in an allergic reaction by increasing interleukin-4 production and immunoglobulin E levels.[13]

Enhancing Healthcare Team Outcomes

The interprofessional health care team, such as physicians, nurses, and pharmacists, play an essential role in monitoring patients on hydroquinone. It is important to monitor patients to ensure that they only use the medication as prescribed for no more than 5 to 6 months to limit side effects. Nursing staff can play a significant role in monitoring the patient and evaluating compliance, as it is important to follow instructions for the medication application, its frequency, keep a watchful eye for any adverse effect, which should be clearly explained to the patient. Patients should be instructed to cease using the medication if any irritation, hypersensitivity, or allergic reaction occurs. Pharmacists can review the use and adverse events when dispensing the drug, and monitor when the patient comes in for refills, alerting the prescribing clinician regarding any concerns. The rare, yet most potentially harmful, side effect of ochronosis needs to be explained to patients using hydroquinone, and they should be instructed to discontinue this medication immediately if this occurs. A collaborative interprofessional team approach to hydroquinone therapy will guide outcomes most effectively. [Level 5]

Review Questions


Epstein JH. Postinflammatory hyperpigmentation. Clin Dermatol. 1989 Apr-Jun;7(2):55-65. [PubMed: 2667741]
Stephens TJ, Babcock M, Bucay V, Gotz V. Split-face Evaluation of a Multi-ingredient Brightening Foam Versus a Reference Control in Women with Photodamaged Facial Skin. J Clin Aesthet Dermatol. 2018 Oct;11(10):24-28. [PMC free article: PMC6239159] [PubMed: 30519376]
Tomita Y, Maeda K, Tagami H. Mechanisms for hyperpigmentation in postinflammatory pigmentation, urticaria pigmentosa and sunburn. Dermatologica. 1989;179 Suppl 1:49-53. [PubMed: 2550287]
Katsambas AD, Stratigos AJ. Depigmenting and bleaching agents: coping with hyperpigmentation. Clin Dermatol. 2001 Jul-Aug;19(4):483-8. [PubMed: 11535393]
Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol. 1999;455:491-9. [PubMed: 10599387]
Sofen B, Prado G, Emer J. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion. Skin Therapy Lett. 2016 Jan;21(1):1-7. [PubMed: 27224897]
Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, Lim HW, Hamzavi IH. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010 Aug;130(8):2092-7. [PubMed: 20410914]
Lieberman R, Moy L. Estrogen receptor expression in melasma: results from facial skin of affected patients. J Drugs Dermatol. 2008 May;7(5):463-5. [PubMed: 18505139]
Speeckaert R, Van Gele M, Speeckaert MM, Lambert J, van Geel N. The biology of hyperpigmentation syndromes. Pigment Cell Melanoma Res. 2014 Jul;27(4):512-24. [PubMed: 24612852]
Bozzo P, Chua-Gocheco A, Einarson A. Safety of skin care products during pregnancy. Can Fam Physician. 2011 Jun;57(6):665-7. [PMC free article: PMC3114665] [PubMed: 21673209]
Rendon MI, Barkovic S. Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI. J Drugs Dermatol. 2016 Nov 01;15(11):1435-1441. [PubMed: 28095558]
Choukem SP, Efie DT, Djiogue S, Kaze FF, Mboue-Djieka Y, Boudjeko T, Dongo E, Gautier JF, Kengne AP. Effects of hydroquinone-containing creams on capillary glycemia before and after serial hand washings in Africans. PLoS One. 2018;13(8):e0202271. [PMC free article: PMC6112636] [PubMed: 30153255]
Enguita FJ, Leitão AL. Hydroquinone: environmental pollution, toxicity, and microbial answers. Biomed Res Int. 2013;2013:542168. [PMC free article: PMC3727088] [PubMed: 23936816]

Disclosure: Chelsea Schwartz declares no relevant financial relationships with ineligible companies.

Disclosure: Arif Jan declares no relevant financial relationships with ineligible companies.

Disclosure: Patrick Zito declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK539693PMID: 30969515


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...